Skip to content

OCSAW: Held by 2 Biotech Hedge Funds (2026) | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Sign In Start 14-Day Free Trial

Home›Companies›Oculis Holding AG (OCSAW)

Oculis Holding AG

OCSAW

Held by 2 specialist biotech funds

2 funds opened new positions. Next phase2 readout (OCS-01): Jun 2026.

Share

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

4.0/10

2 funds opened new positions

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

●●

No recent insider activity●●

Phase3 readout expected Dec 2026●●

Held by 2 specialist funds●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Conviction + Catalyst

2 specialist funds hold OCSAW with a Phase 3 in 172 days for licaminlimab (Dry Eye Disease (DED))

+1 more upcoming catalyst

Perceptive Advisors Eventide Asset Management

Fund Holdings

Perceptive AdvisorsHeld 2Q

Eventide Asset ManagementNew

Position history (shares)

Perceptive Advisors

2Q

AI Signal

Oculis Holding AG (OCSAW) — New Position Signal

Eventide Asset Management initiated a $11.4M position (430,000 shares) in Oculis, a values-aligned fund with meaningful biotech exposure making a fresh bet on two near-term ophthalmology catalysts: a Phase 2 readout for OCS-01 in uveitis-related cystoid macular edema (mid-2026) and a Phase 3 readout for licaminlimab in dry eye disease (end-2026), the latter representing a high-value commercial indication with significant unmet need. Specialist fund convergence — Perceptive Advisors also holds the name — elevates this to a high-conviction signal given Perceptive's track record in ophthalmology and clinical-stage biotech.

Unlock full AI analysis — 14-day free trial

2 quarters

Position Trend

Feb 17, 2026

$9.9M

1 fund

May 15, 2026

$11.4M

1 fund

May 29, 2026

$13.1M

1 fund

+33% total institutional value over 3 quarters

Catalysts

Phase 2Q2 2026OCS-01Uveitis Related Cystoid Macular Edema, Cystoid Macular Edema, PostoperativeNCT05608837

Phase 3Q4 2026licaminlimabDry Eye Disease (DED)NCT07548632

Phase 3Q4 2027PrivosegtorOptic NeuritisNCT07623668

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Position Details

Perceptive AdvisorsHELDMay 29, 2026

Start free trialfor share counts, dollar values & AI analysis

2 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Also Held by These Funds

COGT1 fund ENGNW1 fund CTNM1 fund CBIO1 fund ENSCW1 fund MDLN1 fund MGTX1 fund NAUT1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts: